| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
23,480,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Talis Biomedical is engaged in transforming diagnostic testing by developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions at the point of care. Co. is developing the Talis One system, a cloud-enabled molecular diagnostic platform. The Talis One system comprises an instrument, single-use test cartridges and software that is designed to support a central cloud database, which are designed to provide central laboratory levels of accuracy and be operated by an untrained user. Co. is developing Talis One assay kits for respiratory infections, and infections related to women's health and sexually transmitted infection.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Baker Brothers Life Sciences Lp |
Director |
– • • |
2021-11-18 |
4 |
B |
$4.37 |
$218,250 |
I/I |
50,000 |
7,053,176 |
2.25 |
- |
|
| Ramakrishnan Ramesh |
Former Officer |
– – – |
2021-08-13 |
4 |
S |
$7.66 |
$210,665 |
D/D |
(27,502) |
38,619 |
|
- |
|
| Ramakrishnan Ramesh |
Former Officer |
– – – |
2021-08-13 |
4 |
OE |
$1.50 |
$78,533 |
D/D |
52,355 |
66,121 |
|
- |
|
| Scott Randal W |
Director |
– • – |
2021-05-17 |
4 |
B |
$10.11 |
$111,210 |
D/D |
11,000 |
20,000 |
2.39 |
- |
|
| Scott Randal W |
Director |
– • – |
2021-05-14 |
4 |
B |
$10.16 |
$91,440 |
D/D |
9,000 |
9,000 |
2.39 |
- |
|
| Moody John Roger Jr |
Chief Financial Officer |
• – – |
2021-02-17 |
4 |
B |
$16.00 |
$27,200 |
D/D |
1,700 |
1,700 |
2.74 |
- |
|
| Coe Brian |
Chief Executive Officer |
• • – |
2021-02-17 |
4 |
A |
$0.00 |
$0 |
I/I |
30,931 |
33,486 |
|
- |
|
| Scott Randal W |
Director |
– • – |
2021-02-17 |
4 |
B |
$16.00 |
$5,000,000 |
I/I |
312,500 |
312,500 |
2.1 |
- |
|
| Scott Randal W |
Director |
– • – |
2021-02-17 |
4 |
A |
$0.00 |
$0 |
I/I |
1,390,064 |
1,390,064 |
|
- |
|
| Liu Douglas |
Sr. Vice President, Operations |
• – – |
2021-02-17 |
4 |
B |
$16.00 |
$64,000 |
D/D |
4,000 |
4,000 |
2.74 |
- |
|
| Popovits Kimberly J |
Director |
– • – |
2021-02-17 |
4 |
A |
$0.00 |
$0 |
I/I |
391,815 |
182,025 |
|
- |
|
| Popovits Kimberly J |
Director |
– • – |
2021-02-17 |
4 |
B |
$16.00 |
$84,800 |
I/I |
5,300 |
215,090 |
2.1 |
- |
|
| Popovits Kimberly J |
Director |
– • – |
2021-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
22,041 |
25,776 |
|
- |
|
| Ramakrishnan Ramesh |
Sr. Vice President, R&D |
• – – |
2021-02-17 |
4 |
B |
$16.00 |
$16,000 |
D/D |
1,000 |
1,000 |
2.74 |
- |
|
| Posard Matthew L. |
Director |
– • – |
2021-02-17 |
4 |
B |
$16.00 |
$1,000,000 |
D/D |
62,500 |
62,500 |
2.39 |
- |
|
| Baker Julian |
Director |
– • • |
2021-02-17 |
4 |
B |
$16.00 |
$100,000,000 |
I/I |
6,250,000 |
7,003,176 |
2.25 |
- |
|
| Flick Karen E. |
Chief of Staff, Sr. VP, Legal |
• – – |
2021-02-17 |
4 |
B |
$16.00 |
$32,000 |
D/D |
2,000 |
2,000 |
2.74 |
- |
|
| Ismagilov Rustem F. |
Director |
– • – |
2021-02-11 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
146,222 |
|
- |
|
| Ismagilov Rustem F. |
Director |
– • – |
2021-02-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
119,440 |
|
- |
|
| Coe Brian |
Chief Executive OfficerOfficer |
• • – |
2021-02-11 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
10,387 |
|
- |
|
| Coe Brian |
Chief Executive OfficerOfficer |
• • – |
2021-02-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
58,881 |
|
- |
|
| Popovits Kimberly J |
Director |
– • – |
2021-02-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,735 |
|
- |
|
| Baker Julian |
Director |
– • • |
2021-02-11 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,325,425 |
|
- |
|
23 Records found
|
1
|
Page 1 of 1 |
|
|
